AtheroGenics to Report Second Quarter 2008 Financial Results on August 5, 2008
July 25 2008 - 7:15AM
Marketwired
ATLANTA, GA , a pharmaceutical company focused on the treatment
of chronic inflammatory diseases, today announced that it will
release its second quarter 2008 financial results on Tuesday,
August 5, 2008 before the U.S. financial markets open.
Conference Call and Webcast Information
Company officials will discuss second quarter 2008 financial
results via conference call and webcast on Tuesday, August 5, 2008,
at 9:00 a.m. EDT. Participants may access the live conference call
by dialing 877-407-8031 (domestic) or 201-689-8031 (international).
To access the webcast, please visit the AtheroGenics Investor
Relations website at www.atherogenics.com. A replay of the
conference call will be accessible approximately one hour after the
conclusion of the call by dialing 877-660-6853 (domestic) or
201-612-7415 (international), account number 286, conference ID
number 292374. A replay of the webcast will be archived on the
Company's website until November 6, 2008.
About AtheroGenics
AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including diabetes and coronary heart
disease (atherosclerosis). The Company's lead product candidate,
AGI-1067, is a novel antioxidant and anti-inflammatory agent that
is currently being evaluated in a Phase III registration study
called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation
Study) as an oral treatment for Type 2 diabetes. In addition, the
Company has other clinical and preclinical anti-inflammatory
compounds, including AGI-1096, an oral agent for the prevention of
organ transplant rejection. For more information about
AtheroGenics, please visit http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Mark P. Colonnese Executive Vice
President 678-336-2511 Email Contact Media Inquiries Jayme Maniatis
/ Dana Conti Schwartz Communications, Inc. 781-684-0770 Email
Contact Investor Inquiries Lilian Stern Stern Investor Relations,
Inc. 212-362-1200 Email Contact
KraneShares Artificial I... (NASDAQ:AGIX)
Historical Stock Chart
From Dec 2024 to Jan 2025
KraneShares Artificial I... (NASDAQ:AGIX)
Historical Stock Chart
From Jan 2024 to Jan 2025
